242 related articles for article (PubMed ID: 18157138)
1. Successful treatment of canine leukocyte adhesion deficiency by foamy virus vectors.
Bauer TR; Allen JM; Hai M; Tuschong LM; Khan IF; Olson EM; Adler RL; Burkholder TH; Gu YC; Russell DW; Hickstein DD
Nat Med; 2008 Jan; 14(1):93-7. PubMed ID: 18157138
[TBL] [Abstract][Full Text] [Related]
2. Long-term follow-up of foamy viral vector-mediated gene therapy for canine leukocyte adhesion deficiency.
Bauer TR; Tuschong LM; Calvo KR; Shive HR; Burkholder TH; Karlsson EK; West RR; Russell DW; Hickstein DD
Mol Ther; 2013 May; 21(5):964-72. PubMed ID: 23531552
[TBL] [Abstract][Full Text] [Related]
3. Treatment of canine leukocyte adhesion deficiency by foamy virus vectors expressing CD18 from a PGK promoter.
Bauer TR; Olson EM; Huo Y; Tuschong LM; Allen JM; Li Y; Burkholder TH; Russell DW
Gene Ther; 2011 Jun; 18(6):553-9. PubMed ID: 21228879
[TBL] [Abstract][Full Text] [Related]
4. Gene therapy of canine leukocyte adhesion deficiency using lentiviral vectors with human CD11b and CD18 promoters driving canine CD18 expression.
Hunter MJ; Tuschong LM; Fowler CJ; Bauer TR; Burkholder TH; Hickstein DD
Mol Ther; 2011 Jan; 19(1):113-21. PubMed ID: 20859258
[TBL] [Abstract][Full Text] [Related]
5. Correction of the disease phenotype in canine leukocyte adhesion deficiency using ex vivo hematopoietic stem cell gene therapy.
Bauer TR; Hai M; Tuschong LM; Burkholder TH; Gu YC; Sokolic RA; Ferguson C; Dunbar CE; Hickstein DD
Blood; 2006 Nov; 108(10):3313-20. PubMed ID: 16868255
[TBL] [Abstract][Full Text] [Related]
6. Gene therapy for canine leukocyte adhesion deficiency with lentiviral vectors using the murine stem cell virus and human phosphoglycerate kinase promoters.
Hunter MJ; Zhao H; Tuschong LM; Bauer TR; Burkholder TH; Persons DA; Hickstein DD
Hum Gene Ther; 2011 Jun; 22(6):689-96. PubMed ID: 21275758
[TBL] [Abstract][Full Text] [Related]
7. Preclinical Evaluation of Foamy Virus Vector-Mediated Gene Addition in Human Hematopoietic Stem/Progenitor Cells for Correction of Leukocyte Adhesion Deficiency Type 1.
Smith RH; Bloomer H; Fink D; Keyvanfar K; Nasimuzzaman M; Sancheznieto F; Dutta R; Guenther Bui K; Alvarado LJ; Bauer TR; Hickstein DD; Russell DW; Malik P; van der Loo JCM; Highfill SL; Kuhns DB; Pirooznia M; Larochelle A
Hum Gene Ther; 2022 Dec; 33(23-24):1293-1304. PubMed ID: 36094106
[No Abstract] [Full Text] [Related]
8. Lentiviral vectors incorporating a human elongation factor 1alpha promoter for the treatment of canine leukocyte adhesion deficiency.
Nelson EJ; Tuschong LM; Hunter MJ; Bauer TR; Burkholder TH; Hickstein DD
Gene Ther; 2010 May; 17(5):672-7. PubMed ID: 20164857
[TBL] [Abstract][Full Text] [Related]
9. Potential genotoxicity from integration sites in CLAD dogs treated successfully with gammaretroviral vector-mediated gene therapy.
Hai M; Adler RL; Bauer TR; Tuschong LM; Gu YC; Wu X; Hickstein DD
Gene Ther; 2008 Jul; 15(14):1067-71. PubMed ID: 18369320
[TBL] [Abstract][Full Text] [Related]
10. Foamy virus vectors come of age.
Williams DA
Mol Ther; 2008 Apr; 16(4):635-6. PubMed ID: 18362918
[No Abstract] [Full Text] [Related]
11. Conversion of the severe to the moderate disease phenotype with donor leukocyte microchimerism in canine leukocyte adhesion deficiency.
Gu YC; Bauer TR; Sokolic RA; Hai M; Tuschong LM; Burkholder T; Bacher J; Starost MF; Hickstein DD
Bone Marrow Transplant; 2006 Mar; 37(6):607-14. PubMed ID: 16444276
[TBL] [Abstract][Full Text] [Related]
12. Foamy Virus Vector Carries a Strong Insulator in Its Long Terminal Repeat Which Reduces Its Genotoxic Potential.
Goodman MA; Arumugam P; Pillis DM; Loberg A; Nasimuzzaman M; Lynn D; van der Loo JCM; Dexheimer PJ; Keddache M; Bauer TR; Hickstein DD; Russell DW; Malik P
J Virol; 2018 Jan; 92(1):. PubMed ID: 29046446
[TBL] [Abstract][Full Text] [Related]
13. Tracking of specific integrant clones in dogs treated with foamy virus vectors.
Ohmine K; Li Y; Bauer TR; Hickstein DD; Russell DW
Hum Gene Ther; 2011 Feb; 22(2):217-24. PubMed ID: 20738155
[TBL] [Abstract][Full Text] [Related]
14. Unique integration profiles in a canine model of long-term repopulating cells transduced with gammaretrovirus, lentivirus, or foamy virus.
Beard BC; Keyser KA; Trobridge GD; Peterson LJ; Miller DG; Jacobs M; Kaul R; Kiem HP
Hum Gene Ther; 2007 May; 18(5):423-34. PubMed ID: 17518616
[TBL] [Abstract][Full Text] [Related]
15. Nonmyeloablative conditioning with busulfan before matched littermate bone marrow transplantation results in reversal of the disease phenotype in canine leukocyte adhesion deficiency.
Sokolic RA; Bauer TR; Gu YC; Hai M; Tuschong LM; Burkholder T; Colenda L; Bacher J; Starost MF; Hickstein DD
Biol Blood Marrow Transplant; 2005 Oct; 11(10):755-63. PubMed ID: 16182176
[TBL] [Abstract][Full Text] [Related]
16. Foamy virus vectors: an awaited alternative to gammaretro- and lentiviral vectors.
Rethwilm A
Curr Gene Ther; 2007 Aug; 7(4):261-71. PubMed ID: 17969559
[TBL] [Abstract][Full Text] [Related]
17. Nonmyeloablative hematopoietic stem cell transplantation corrects the disease phenotype in the canine model of leukocyte adhesion deficiency.
Bauer TR; Gu YC; Tuschong LM; Burkholder T; Bacher JD; Starost MF; Donahue RE; Sokolic RA; Hickstein DD
Exp Hematol; 2005 Jun; 33(6):706-12. PubMed ID: 15911095
[TBL] [Abstract][Full Text] [Related]
18. Stem cell selection in vivo using foamy vectors cures canine pyruvate kinase deficiency.
Trobridge GD; Beard BC; Wu RA; Ironside C; Malik P; Kiem HP
PLoS One; 2012; 7(9):e45173. PubMed ID: 23028826
[TBL] [Abstract][Full Text] [Related]
19. Large animal models for foamy virus vector gene therapy.
Trobridge GD; Horn PA; Beard BC; Kiem HP
Viruses; 2012 Dec; 4(12):3572-88. PubMed ID: 23223198
[TBL] [Abstract][Full Text] [Related]
20. Canine leukocyte adhesion deficiency colony for investigation of novel hematopoietic therapies.
Creevy KE; Bauer TR; Tuschong LM; Embree LJ; Colenda L; Cogan K; Starost MF; Haskins ME; Hickstein DD
Vet Immunol Immunopathol; 2003 Jul; 94(1-2):11-22. PubMed ID: 12842608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
